FindTrial
Sign In

Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)

DRUG7 trials

Sponsors

Sanofi

Conditions

AscitesCancer of the OvaryCarcinomaColorectal NeoplasmsNeoplasm MetastasisNeoplasmsNeoplasms, LungNon Small Cell Lung

Phase 2

Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma
CompletedNCT00284141
SanofiNeoplasms, Lung, Pulmonary Diseases
Start: 2006-01-31End: 2008-07-31Updated: 2012-12-10
Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer
CompletedNCT00327171
SanofiCancer of the Ovary, Neoplasms
Start: 2006-05-31End: 2010-03-31Updated: 2016-06-07
Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites
CompletedNCT00327444
SanofiAscites, Ovarian Neoplasms
Start: 2006-07-31End: 2009-10-31Updated: 2013-01-01
AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites
CompletedNCT00396591
SanofiOvarian Neoplasms
Start: 2006-10-31End: 2008-11-30Updated: 2013-01-10

Phase 3

A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
CompletedNCT00532155
SanofiCarcinoma, Non Small Cell Lung
Start: 2007-09-30End: 2011-10-31Updated: 2025-09-10
Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen
CompletedNCT00561470
SanofiColorectal Neoplasms, Neoplasm Metastasis
Start: 2007-11-30End: 2012-06-30Updated: 2012-09-28
Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer
TerminatedNCT00574275
SanofiPancreatic Neoplasm
Start: 2007-12-31End: 2010-11-30Updated: 2016-06-07

Related Papers

Exploratory biomarker analysis of RAS/BRAF somatic mutations and gene expression signatures for predicting treatment effects of aflibercept in the velour trial.
2026-01-13
Deep learning for the prediction of early on-treatment response in metastatic colorectal cancer from serial medical imaging.
2021-11-1754 citations
Clinical significance of site-specific metastases in pancreatic cancer: a study based on both clinical trial and real-world data
Journal of Cancer2021-01-0124 citations
Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer
BMC Cancer2020-11-174 citations
Safety and Effectiveness of Aflibercept + Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study
Cancers2020-03-1115 citations
Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer.
2019-02-2232 citations
Prediction of overall survival for metastatic pancreatic cancer: Development and validation of a prognostic nomogram with data from open clinical trial and real‐world study
Cancer Medicine2018-06-0140 citations
Development and validation of a prognostic nomogram for metastatic pancreatic cancer.
Journal of Clinical Oncology2018-05-20
Prediction of overall survival for metastatic pancreatic cancer treated with gemcitabine monotherapy: Development and external validation of a prognostic nomogram with open clinical trial data.
Journal of Clinical Oncology2018-02-01
Predicting tumour growth and its impact on survival in gemcitabine-treated patients with advanced pancreatic cancer.
2018-01-3115 citations
Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial.
2017-08-1228 citations
Velour trial biomarkers update: Impact of RAS, BRAF, and sidedness on aflibercept activity.
Journal of Clinical Oncology2017-05-2056 citations
European Medicines Agency approval summary: Zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer.
2017-05-0212 citations
Placental growth factor and the angiogenic environment based on analysis of baseline plasma biomarkers from the VELOUR trial.
Journal of Clinical Oncology2017-02-018 citations
A phase II study of ziv-aflibercept (Z) + FOLFIRI in Japanese patients (pts) with metastatic colorectal cancer (mCRC).
Journal of Clinical Oncology2017-02-013 citations
Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy.
2016-06-0126 citations
A retrospective comparison of the ability of lesion volumes and longest diameters to predict clinical outcome in metastatic colorectal cancer.
Journal of Clinical Oncology2015-05-20
The consistency of effect of ziv-aflibercept (Z) in the bevacizumab (B) pre-treated subgroup of patients (pts) in the velour trial stratified by first-line progression ≥ 9 months (mos) versus < 9 mos.
Journal of Clinical Oncology2014-05-203 citations
A preclinical and clinical review of aflibercept for the management of cancer.
2012-01-2081 citations
Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.
2011-12-20107 citations